Literature DB >> 17218256

Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice.

Yasuyoshi Ueki1, Chin-Yu Lin, Makoto Senoo, Takeshi Ebihara, Naoki Agata, Masahiro Onji, Yasunori Saheki, Toshihisa Kawai, Padma M Mukherjee, Ernst Reichenberger, Bjorn R Olsen.   

Abstract

While studies of the adaptor SH3BP2 have implicated a role in receptor-mediated signaling in mast cells and lymphocytes, they have failed to identify its function or explain why SH3BP2 missense mutations cause bone loss and inflammation in patients with cherubism. We demonstrate that Sh3bp2 "cherubism" mice exhibit trabecular bone loss, TNF-alpha-dependent systemic inflammation, and cortical bone erosion. The mutant phenotype is lymphocyte independent and can be transferred to mice carrying wild-type Sh3bp2 alleles through mutant fetal liver cells. Mutant myeloid cells show increased responses to M-CSF and RANKL stimulation, and, through mechanisms of increased ERK 1/2 and SYK phosphorylation/activation, they form macrophages that express high levels of TNF-alpha and osteoclasts that are unusually large. M-CSF and RANKL stimulation of myeloid cells that overexpress wild-type SH3BP2 results in similar large osteoclasts. This indicates that the mutant phenotype reflects gain of SH3BP2 function and suggests that SH3BP2 is a critical regulator of myeloid cell responses to M-CSF and RANKL stimulation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17218256     DOI: 10.1016/j.cell.2006.10.047

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  67 in total

Review 1.  Neutrophilic dermatoses and autoinflammatory diseases with skin involvement--innate immune disorders.

Authors:  Alexander A Navarini; Takashi K Satoh; Lars E French
Journal:  Semin Immunopathol       Date:  2015-11-30       Impact factor: 9.623

2.  SH3BP2 mutations potentiate osteoclastogenesis via PLCγ.

Authors:  Steven A Lietman; Lihong Yin; Michael A Levine
Journal:  J Orthop Res       Date:  2010-11       Impact factor: 3.494

Review 3.  Signaling networks that control the lineage commitment and differentiation of bone cells.

Authors:  Carrie S Soltanoff; Shuying Yang; Wei Chen; Yi-Ping Li
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2009       Impact factor: 1.807

4.  SOS1 and PTPN11 mutations in five cases of Noonan syndrome with multiple giant cell lesions.

Authors:  Claire Beneteau; Hélène Cavé; Anne Moncla; Nathalie Dorison; Arnold Munnich; Alain Verloes; Bruno Leheup
Journal:  Eur J Hum Genet       Date:  2009-04-08       Impact factor: 4.246

5.  Identical Mutation in SH3BP2 Gene Causes Clinical Phenotypes with Different Severity in Mother and Daughter - Case Report.

Authors:  L Preda; O Dinca; A Bucur; C Dragomir; E Severin
Journal:  Mol Syndromol       Date:  2010-06-09

Review 6.  Immunological loss-of-function due to genetic gain-of-function in humans: autosomal dominance of the third kind.

Authors:  Bertrand Boisson; Pierre Quartier; Jean-Laurent Casanova
Journal:  Curr Opin Immunol       Date:  2015-01-31       Impact factor: 7.486

7.  Investigating global gene expression changes in a murine model of cherubism.

Authors:  Tulika Sharma; Justin Cotney; Vijender Singh; Archana Sanjay; Ernst J Reichenberger; Yasuyoshi Ueki; Peter Maye
Journal:  Bone       Date:  2020-03-10       Impact factor: 4.398

8.  Clinicopathologic and Molecular Characteristics of Familial Cherubism with Associated Odontogenic Tumorous Proliferations.

Authors:  Prokopios P Argyris; Rajaram Gopalakrishnan; Ying Hu; Ernst J Reichenberger; Ioannis G Koutlas
Journal:  Head Neck Pathol       Date:  2017-07-18

9.  SH3BP2 is a critical regulator of macrophage and osteoclast response to M-CSF and RANKL stimulation.

Authors:  Mark S McMahon; Yasuyoshi Ueki
Journal:  HSS J       Date:  2008-10-25

10.  Tyrosine phosphorylation of 3BP2 regulates B cell receptor-mediated activation of NFAT.

Authors:  Upasana Shukla; Tomoko Hatani; Kenji Nakashima; Kazuhiro Ogi; Kiyonao Sada
Journal:  J Biol Chem       Date:  2009-10-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.